Skip to main content
Premium Trial:

Request an Annual Quote

Prolexys Raises $20M to Develop Cancer Drug

NEW YORK (GenomeWeb News) - Prolexys Pharmaceuticals announced today that it has received $20 million in a Preferred Series A1 round, which it will use to advance the clinical development of a molecule that has shown anti-tumor activity.
The funding round was led by Friedli Corporate Finance, whose chairman and CEO, Peter Friedli, is on Prolexys’ board.
Based in Salt Lake City, Prolexys develops small-molecule drugs using its proprietary proteomics technology platform. The company had previously raised $85 million. The funds announced today represent the first round since it moved to drug development from proteomics technology development.
Prolexys is currently conducting a Phase 1 study on PRLX 93936, a small molecule that has shown “potent and selective” anti-tumor activity in disease models representative of colon, lung, pancreatic, and ovarian cancer, several sarcoma subtypes, and multiple myeloma. The study is assessing the safety, pharmacokinetics, and pharmacodynamics of PRLX 93936.
The money will be used to further fund the study. It also will be used to develop back-up molecules to PRLX 93936, said Sudhir Sahasrabudhe, scientific founder and CSO of Prolexys, in a statement.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.